48 A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.

47 Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice.

46 Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid.

45 Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis.

44 Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.

43 Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.

42 The MC1R Gene and Youthful Looks.

41 Interleukin-4 Receptor α Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair.

40 Afamelanotide for Erythropoietic Protoporphyria.

39 Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis.

38 Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis.

37 Molecular cartography of the human skin surface in 3D.

36 Mass Treatment with Single-Dose Azithromycin for Yaws.

35 The E3 ubiquitin ligase Itch inhibits p38α signaling and skin inflammation through the ubiquitylation of Tab1.

34 Melanin, a pigment thought to protect against skin cancer, contributes to DNA damage occurring after ultraviolet exposure.

33 A Randomized Trial of Icatibant in ACE-Inhibitor–Induced Angioedema.

32 Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.

31 Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

30 Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

29 Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis.

Free Images for Presentation: sunipix SUNIPIX